About Remegen
Remegen is a company based in Yantai (China) founded in 2008 by Jianmin Fang and Weidong Wang. Remegen has raised $100 million across 1 funding round from investors including Orbimed, Lilly Asia Ventures and Lake Bleu Capital. The company has 3,500 employees as of December 31, 2024. Remegen operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
- Headquarter Yantai, China
- Employees 3500 as on 31 Dec, 2024
- Founders Jianmin Fang, Weidong Wang
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Remegen Co. Ltd. Class A
-
Annual Revenue
$234.27 M (USD)59.12as on Dec 31, 2024
-
Net Profit
-$201.39 M (USD)2.84as on Dec 31, 2024
-
EBITDA
-$158.92 M (USD)13.22as on Dec 31, 2024
-
Total Equity Funding
$100 M (USD)
in 1 rounds
-
Latest Funding Round
$100 M (USD), Private Equity Round
Mar 16, 2020
-
Investors
Orbimed
& 6 more
-
Employee Count
3500
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Remegen
Remegen is a publicly listed company on the SSE with ticker symbol 688331 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Remegen
Remegen has successfully raised a total of $100M through 1 strategic funding round. The most recent funding activity was a Private Equity Round of $100 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Remegen
Remegen has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, Lilly Asia Ventures and Lake Bleu Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Remegen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Remegen
Investment portfolio details for Remegen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Remegen
Detailed financials for Remegen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Remegen Comparisons
Peer comparison for Remegen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Remegen
Remegen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by the company.
|
Detailed competitors of Remegen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Remegen
Complete news archive for Remegen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Remegen
Remegen was founded in 2008 and raised its 1st funding round 12 years after it was founded.
Remegen is headquartered in Yantai, China. It is registered at Yantai, Shandong, China.
Jianmin Fang is the current CEO of Remegen. They have also founded this company.
Remegen is a funded company, having raised a total of $100M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at Remegen is 3,500.
Annual revenue of Remegen is $234.27M as on Dec 31, 2024.
Remegen was established in 2008 in Yantai, China, within the biotechnology sector. Antibody-based and fusion protein technologies are utilized to create treatments for cancer, autoimmune conditions, and eye disorders. Antibody-drug conjugates and bifunctional antibodies form key elements of the platform. A notable drug candidate, R18, is advanced as a fusion protein targeting rheumatoid arthritis. Operations emphasize research and development in these therapeutic areas.
Remegen's top competitors include Moderna, argenx and Forge Biologics.
Yes, Remegen is publicly traded on SSE under the ticker symbol 688331.
Remegen has 7 investors. Key investors include Orbimed, Lilly Asia Ventures, Lake Bleu Capital, Vivo Capital, and Janchor Partners.
The ticker symbol of Remegen is 688331 on SSE.